Steroid-toxicity Insights Roundup

Steroid-toxicity Insights Roundup

We are pleased by the response to our all-new STOX Digital Platform, which launched just last month. Now all STOX licensees can calculate validated scores using any or all of our clinical outcome assessments of steroid-toxicity.

In addition, we’re delighted to provide access to a free trial of the GTI-MD.

Access the free trial >


For those who would prefer a “90-second explainer” to share with their colleagues, we’ve developed a helpful little video - we hope you enjoy it!

Watch the video >


In conversation with... Dan Hawcutt, MD MRCPCH

Dan Hawcutt, MD MRCPCH is a reader in pediatric pharmacology at the University of Liverpool, and honorary consultant in pediatrics at Alder Hey Children’s Hospital. He is the director of Alder Hey’s early-phase clinical research facility, overseeing early-phase drug trials, and testing medicines, including steroids.

Read the full interview >


It’s Time to Protect Asthma Patients From Steroid Overuse

Glucocorticoid overuse represents a failure in asthma treatment planning especially for those with persistent exacerbations. 

Learn more >


Steroid-toxicity and ANCA-associated Vasculitis: How Far Have We Come in 40 Years?

More patients die from complications associated with glucocorticoid treatment than from the underlying disease - but there is hope.

Learn more >


Get all the latest insights here >


Steritas is working toward a world free of steroid dependency, enabling the measurement and monitoring of steroid-toxicity to optimize treatment of inflammatory diseases and improve the quality of patient care around the world.

Learn more at steritas.com.


Sincerely,

Martha Stone

CEO, Steritas

To view or add a comment, sign in

Insights from the community

Others also viewed

Explore topics